ArticleProteome science2025
Identification of noval diagnostic biomarker for HFpEF based on proteomics and machine learning.
Article in Proteome science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Implementation of Machine Learning in Heart Failure Trials.Current heart failure reports · 2026Review
- From Natriuretic Peptides to microRNAs: Multi-Analyte Liquid Biopsy Horizons in Heart Failure.Biomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHeart failure with preserved ejection fraction (HFpEF) is a complex syndrome that currently lacks effective biomarkers for early diagnosis and treatment. This study seeks to identify new potential biomarkers for HFpEF using proteomics and machine learning.
methodsPlasma samples were collected from 20 patients newly diagnosed age, sex, BMI matched HFpEF and 20 healthy controls (HCs). Proteomic analysis was performed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) in data-independent acquisition mode. Differentially expressed proteins (DEPs) were identified and analyzed through enrichment analyses and protein-protein interaction (PPI) network construction. Machine learning methods, including LASSO regression and the Boruta algorithm were used to select candidate biomarkers. The diagnostic value of these proteins was assessed using receiver operating characteristic (ROC) curves and nomogram construction. Expression of candidate proteins was analyzed in immune cells and tissues. Finally, enzyme-linked immunosorbent assay (ELISA) was used to validate the plasma levels of selected proteins.
resultsA total of 34 DEPs were identified between HFpEF patients and HCs. Enrichment analyses revealed involvement in acute-phase response and immune pathways. PPI network analysis identified nine hub proteins. Machine learning methods narrowed the candidates to four potential biomarkers: SERPINA1, AFM, SERPINA3, and ITIH4. Among these, SERPINA3 showed the highest diagnostic value with an area under the ROC curve (AUC) of 0.835. ELISA validation confirmed that plasma SERPINA3 levels were significantly elevated in HFpEF patients compared to HCs (p < 0.0001).
conclusionsOur findings suggest that SERPINA3 could serve as a biomarker for HFpEF, Elevated plasma levels of SERPINA3 in HFpEF patients suggest its utility in early diagnosis and may provide insights into the disease's pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.